Nonalcoholic Fatty Liver Disease: Status Quo

Area of Science:

• Hepatology
• Gastroenterology
• Metabolic Syndrome

Background:

• Nonalcoholic fatty liver disease (NAFLD) is a growing concern for liver specialists.
• NAFLD includes non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), with NASH linked to cirrhosis and hepatocellular carcinoma (HCC).
• NAFLD is the liver manifestation of metabolic syndrome, increasing risks for liver-related mortality, cardiovascular disease, and malignancies.

Purpose of the Study:

• Provide an evidence-based review on NAFLD pathogenesis, diagnosis, and therapy.
• Update gastroenterologists and hepatologists on recent advancements in NAFLD management.
• Highlight the importance of distinguishing between NAFL and NASH for prognosis and treatment.

Main Methods:

• Review of evidence-based data on NAFLD.
• Discussion of diagnostic tools including noninvasive tests (biomarkers, elastography) and liver biopsy.
• Emphasis on lifestyle modifications and current therapeutic strategies.

Main Results:

• NAFLD is associated with increased overall and liver-related mortality.
• Noninvasive methods are valuable for NAFLD patient evaluation.
• Liver biopsy is indicated for specific diagnostic, therapeutic, and prognostic scenarios.
• Lifestyle changes (weight loss, diet, exercise) are crucial for NAFLD patients.
• Pharmacotherapy is primarily for NASH patients with significant fibrosis, with no FDA-approved NASH therapies currently.

Conclusions:

• NAFLD requires updated clinical knowledge for effective management.
• Differentiating NAFL from NASH is critical due to differing prognoses.
• A multi-faceted approach involving lifestyle changes and targeted pharmacotherapy (for NASH) is essential.
• Further research is needed for FDA-approved NASH therapies.